{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060943","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.021429+00:00","generated_at":"2026-06-15T00:37:54.140694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Onconova Q1 net loss $5.8M; rigosertib achieves complete responses in RDEB-SCC","bullets":["Cash $34.2M as of March 31, 2023; expects runway into Q1 2024.","Net loss $5.8M ($0.28/sh) vs $4.1M ($0.20/sh) in Q1 2022; R&D expenses doubled to $4.1M.","First patient dosed in Phase 1/2a trial of narazaciclib plus letrozole in LGEEC; preliminary data expected Q4 2023.","Both evaluable patients in rigosertib RDEB-SCC trial achieved complete cutaneous remissions; FDA Type B meeting requested.","Entered collaboration with Pangea Biomed to identify biomarkers for rigosertib response."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060943","json":"https://secwatch.observer/filing/0001104659-23-060943.json","markdown":"https://secwatch.observer/filing/0001104659-23-060943.md","text":"https://secwatch.observer/filing/0001104659-23-060943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/0001104659-23-060943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/tm2315886d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:37:54.140694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1947fecd7faaeb7bf6f01f19c695ac5fb5cd12a0","claim":"Traws Pharma, Inc. reported the three months ended March 31, 2023 results: net income $5.8 million, EPS $0.28 per share.","evidence_excerpt":"Net loss for the first quarter of 2023 was $5.8 million, or $0.28 per share on 20.9 million weighted shares outstanding, compared with a net loss of $4.1 million, or $0.20 per share for the first quarter of 2022 on 20.9 million weighted shares outstanding.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/0001104659-23-060943-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$5.8 million"},{"label":"EPS","value":"$0.28 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}